Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26694465 | 1.00 | LCK (0.42) | LCKATRCA12CA1CA9 | |
| SCHEMBL16134075 | 0.81 | ATR (0.41) | LCKATRCA12CA1CA9 | |
| SCHEMBL26694800 | 0.79 | SMN1; SMN2 (0.37) | CA1MEN1NPC1HTTRAB9A | |
| SCHEMBL30843786 | 0.79 | NLRP3 (0.43) | LCK | |
| SCHEMBL31124321 | 0.78 | ATR (0.41) | LCKATRCA12CA1CA9 | |
| SCHEMBL6523050 | 0.78 | ATR (0.40) | LCKATRAAK1MEN1NPC1 | |
| SCHEMBL31290291 | 0.77 | CTSS (0.42) | ATRCA1MEN1KMT2A | |
| SCHEMBL6524156 | 0.77 | LCK (0.40) | LCKAAK1MEN1NPC1HTT | |
| SCHEMBL28911936 | 0.77 | ATR (0.39) | LCKATRCA12CA1CA9 | |
| SCHEMBL31716085 | 0.77 | LCK (0.45) | LCKATRAAK1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025049274-A2 | TETRACYCLIC DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | LCK 743/4885ATR 1848/4885CA12 213/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | LCK 743/4885ATR 1848/4885CA12 213/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | LCK 2078/4885ATR 974/4885CA12 346/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | LCK 743/4885ATR 1848/4885CA12 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.